Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Context Therapeutics ( (CNTX) ) has issued an update.
On May 14, 2026, Context Therapeutics amended its 2024 exclusive license agreement with BioAtla for certain antibody assets, including its Nectin-4 x CD3 T cell engager CT-202. In exchange for a $4.5 million payment within five business days of the amendment and a further $2 million due by August 1, 2026, Context secured irrevocable, royalty-free, fully paid-up and non-terminable licenses to the antibodies.
The amendment removes BioAtla’s rights to terminate the agreement, eliminates Context’s research, development and certain reporting obligations for the licensed antibodies, and cancels all future milestone and royalty payments to BioAtla. The move, announced in a May 18, 2026 press release, gives Context full economic rights to CT-202 as it prepares to advance the program, with Phase 1 clinical testing planned to begin in the third quarter of 2026.
The most recent analyst rating on (CNTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn) with only partial support from a low-debt balance sheet. Technicals are neutral-to-mixed, while valuation is constrained by negative earnings and no dividend. Corporate events provide some upside via FDA Fast Track and governance improvements, but they do not fully offset the core financial risk profile.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, a Claudin 6 x CD3 T cell engager, CT-95, a Mesothelin x CD3 T cell engager, and CT-202, a Nectin-4 x CD3 T cell engager, with operations headquartered in Philadelphia and shares listed on Nasdaq as CNTX.
The company targets clinically validated tumor-associated antigens such as Nectin-4, which is highly expressed in multiple solid tumors including bladder, colorectal, lung and breast cancers. By designing pH-dependent T cell engagers that are preferentially active in the tumor microenvironment, Context aims to enhance antitumor activity while potentially mitigating adverse events observed with traditional antibody-drug conjugates.
Average Trading Volume: 840,933
Technical Sentiment Signal: Buy
Current Market Cap: $198.5M
For an in-depth examination of CNTX stock, go to TipRanks’ Overview page.